A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus.

Trial Profile

A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2016

At a glance

  • Drugs CC 11050 (Primary)
  • Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Mar 2012 Actual initiation date changed from Feb 2011 to Oct 2010 as reported by ClinicalTrials.gov.
    • 05 Mar 2012 Additional lead trial investigator (Tong Li) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top